Innovative Approaches in the Management
of Overactive Bladder (OAB): Managed Care Strategies for Improved
Clinical and Economic Outcomes
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2022 Fall
Managed Care Forum. If you participated in the live session, you are
not eligible for continuing education credits from this archive.
This activity is valid from March 1, 2023 to March 1, 2024
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Overactive bladder (OAB) is a highly prevalent condition that
approximately 17% of women and 16% of men over 18 suffer from,
that’s an estimated 33 million people; however the numbers may be
higher due to undiagnosed cases. OAB occurs about twice as
frequently in women as in men, and while OAB is not considered a
normal part of aging, it does become more prevalent with advanced
age. OAB has a significant impact on quality of life (QoL),
co-morbidities and cost; sufferers are two to three times more
likely to experience disturbed sleep, overeating, poor self-esteem,
and depression. This activity will discuss important information
regarding the consequences and clinical, societal, and economic
burden of underdiagnosed and mismanaged overactive bladder,
available data around the optimal cost and efficacy data around
treatments and their side-effects, updates on the treatment of NDO
in pediatric patients, payer challenges and strategies to achieve
optimal cost management and strategies for individualized therapy
and improved patient adherence. Attendees will leave with ability to
optimize the management of OAB and improve patient adherence and
will be able to use that knowledge to educate their staff and
colleagues, which will ultimately increase organizational quality
and, most importantly, improve outcomes and quality of life in
patients with overactive bladder.
Upon completion of this
activity, participants will be able to:
Examine the clinical and economic
burden of overactive bladder (OAB) in terms of health care
resource utilization, indirect costs, and member quality of life
Discuss communication and diagnostic
techniques for early detection and diagnosis of OAB among
Compare and contrast the efficacy
and safety profiles of new and emerging agents, including the
antimuscarinics, beta-3 agonists and combination therapy, in the
management of OAB
Examine the role of novel treatments
for the management of neurogenic detrusor overactivity (NDO) in
Review patient factors to consider
when selecting between anticholinergics and beta-3 adrenoceptor
agonists for OAB treatment
Analyze benefit design strategies
for clinicians and managed care professionals to improve overall
patient outcomes in OAB
||Matt T. Rosenberg, MD
Mid-Michigan Health Centers
|(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Rosenberg has served as a consultant for Astellas
and Urovant. He serves on the speaker's bureau for
Astellas and Urovant. His presentation has been peer
reviewed for any bias.
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an
educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue